140
|
336
|
8gsjA |
Apc-asef tripeptide inhibitor |
100
|
270
|
7f80A |
Co-crystal structure of inhibitor compound ma-211 in complex with human ppardelta lbd |
133
|
502
|
6l3yA |
Crystal structure of lysyl-trna synthetase from plasmodium falciparum complexed with l-lysine and clado-c |
0
|
9
|
7k29P |
Kelch domain of human keap1 bound to nrf2 peptide, ldeetgeal |
62
|
283
|
7k29A |
Kelch domain of human keap1 bound to nrf2 peptide, ldeetgeal |
0
|
9
|
7k2aP |
Kelch domain of human keap1 bound to nrf2 peptide, ldeetgefa |
58
|
282
|
7k2eA |
Kelch domain of human keap1 bound to nrf2-based cyclic peptide, c[gdeetge] |
0
|
6
|
7k2pP |
Kelch domain of human keap1 bound to nrf2-based cyclic peptide, c[ava-dpetge] |
0
|
6
|
7k2nP |
Kelch domain of human keap1 bound to nrf2-based cyclic peptide, c[bal-deetge] |
0
|
7
|
7k2eP |
Kelch domain of human keap1 bound to nrf2-based cyclic peptide, c[gdeetge] |
64
|
286
|
7k2bA |
Kelch domain of human keap1 bound to nrf2 peptide, adeetgefa |
66
|
288
|
7k2hA |
Kelch domain of human keap1 bound to nrf2 cyclic peptide, c[gdpetge] |
0
|
6
|
7k2oP |
Kelch domain of human keap1 bound to nrf2-based cyclic peptide, c[gaba-dpetge] |
0
|
6
|
7k2sP |
Kelch domain of human keap1 bound to nrf2 cyclic peptide, c[dha-gdpetge] |
0
|
7
|
7k2hP |
Kelch domain of human keap1 bound to nrf2 cyclic peptide, c[gdpetge] |
58
|
283
|
7k2pA |
Kelch domain of human keap1 bound to nrf2-based cyclic peptide, c[ava-dpetge] |
0
|
9
|
7k2bP |
Kelch domain of human keap1 bound to nrf2 peptide, adeetgefa |
63
|
283
|
7k2aA |
Kelch domain of human keap1 bound to nrf2 peptide, ldeetgefa |
57
|
283
|
7k2nA |
Kelch domain of human keap1 bound to nrf2-based cyclic peptide, c[bal-deetge] |
61
|
283
|
7k2oA |
Kelch domain of human keap1 bound to nrf2-based cyclic peptide, c[gaba-dpetge] |
0
|
7
|
7k2gP |
Kelch domain of human keap1 bound to nrf2 cyclic peptide, c[gdeeage] |
70
|
288
|
7k2kA |
Kelch domain of human keap1 bound to nrf2 cyclic peptide, c[bal-deetge] |
59
|
284
|
7k2sA |
Kelch domain of human keap1 bound to nrf2 cyclic peptide, c[dha-gdpetge] |
0
|
6
|
7k2kP |
Kelch domain of human keap1 bound to nrf2 cyclic peptide, c[bal-deetge] |
67
|
288
|
7k2gA |
Kelch domain of human keap1 bound to nrf2 cyclic peptide, c[gdeeage] |
0
|
12
|
6opjB |
Menin in complex with peptide inhibitor 25 |
187
|
478
|
6opjA |
Menin in complex with peptide inhibitor 25 |
1
|
8
|
6keyB |
Structural basis for the regulation of inducible nitric oxide synthase (inos) by the spry domain-containing socs box protein 2 (spsb2) |
53
|
200
|
6keyA |
Structural basis for the regulation of inducible nitric oxide synthase (inos) by the spry domain-containing socs box protein 2 (spsb2) |
1
|
13
|
6pw8B |
Hydrocarbon-stapled paxillin peptide bound to the focal adhesion targeting (fat) domain of the focal adhesion kinase (fak) |
57
|
126
|
6pw8A |
Hydrocarbon-stapled paxillin peptide bound to the focal adhesion targeting (fat) domain of the focal adhesion kinase (fak) |
67
|
285
|
6v6zA |
Crystal structure of n-(4-((4-methoxy-n-(2,2,2-trifluoroethyl)phenyl)sulfonamido)isoquinolin-1-yl)-n-((4-methoxyphenyl)sulfonyl)glycine bound to human keap1 kelch domain |
51
|
193
|
6jwnA |
Crystal structure of the spry domain of spsb2 in complex with cr9, a cyclic peptide inhibitor of spsb-inos interaction |
0
|
7
|
6jwmB |
Crystal structure of the spry domain of spsb2 in complex with cr7, a potent cyclic peptide inhibitor of spsb2-inos interaction |
56
|
203
|
6jwmA |
Crystal structure of the spry domain of spsb2 in complex with cr7, a potent cyclic peptide inhibitor of spsb2-inos interaction |
0
|
9
|
6jwnB |
Crystal structure of the spry domain of spsb2 in complex with cr9, a cyclic peptide inhibitor of spsb-inos interaction |
105
|
305
|
6pgdA |
Wdr5delta32 bound to peptidomimetic |
97
|
305
|
6pgaA |
Wdr5delta32 bound to methyl (4-(4-(hydroxymethyl)-1h-imidazol-2-yl)butyl)carbamate |
104
|
305
|
6pgcA |
Wdr5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1h-imidazol-2-yl)butyl)carbamate |
99
|
305
|
6pg7A |
Wdr5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1h-imidazol-4-yl)methanol |
104
|
305
|
6pgfA |
Wdr5delta32 bound to n-(4-(4-(hydroxymethyl)-1h-imidazol-2-yl)butyl)acrylamide |
103
|
304
|
6pg9A |
Wdr5delta23 bound to n-(4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl)benzamide |
104
|
305
|
6pg4A |
Wdr5delta32 bound to (2-methyl-1h-imidazol-4-yl)methanol |
102
|
305
|
6pg5A |
Wdr5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl)carbamate |
102
|
304
|
6pg3A |
Wdr5delta23 bound to (2-butyl-1h-imidazol-4-yl)methanol |
103
|
305
|
6pgbA |
Wdr5delta32 bound to n-(4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl)-2-phenylacetamide |
104
|
304
|
6pg8A |
Wdr5delta23 bound to (2-(3-phenylpropyl)-1h-imidazol-4-yl)methanol |
102
|
304
|
6pg6A |
Wdr5delta23 bound to n-(4-(5-(hydroxymethyl)-1h-imidazol-2-yl)butyl)acetamide |
100
|
305
|
6pgeA |
Wdr5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1h-imidazol-2-yl)propanoate |
38
|
127
|
6mh7A |
Crystal structure of the first bromodomain of human brd4 in complex with skt-68, a 1,4,5-trisubstituted imidazole analogue |